SCHEMBL5463302

SCHEMBL5463302

Cc1cccc(CNC(=O)c2cn(CCCN3CCC(N4CCCC4)CC3)c3ccccc23)c1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 3/20 0.48
LMNA P02545 1/20 0.46
PTPN7 P35236 1/20 0.44
CNR2 P34972 4/20 0.44
F10 P00742 1/20 0.44
P2RX7 Q99572 1/20 0.44
SMYD2 Q9NRG4 2/20 0.43
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
HPGD P15428 1/20 0.42
HSD17B10 Q99714 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
BCHE P06276 1/20 0.42
ACHE P22303 1/20 0.42
DRD4 P21917 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5453545 0.90 HDAC1 (0.48) CNR1LMNAPTPN7CNR2F10
SCHEMBL14411475 0.87 CNR1 (0.51) CNR1LMNAPTPN7BCHEACHE
SCHEMBL5442965 0.86 BCHE (0.49) CNR1LMNAPTPN7CNR2F10
SCHEMBL5455060 0.85 HDAC1 (0.59) CNR1LMNAPTPN7CNR2P2RX7
SCHEMBL5446833 0.83 CNR2 (0.47) CNR1CNR2P2RX7SMYD2HDAC1
SCHEMBL5461697 0.83 SMN1; SMN2 (0.46) CNR1LMNACNR2P2RX7ALDH1A1
SCHEMBL5455194 0.82 PTPN7 (0.45) CNR1LMNAPTPN7CNR2F10
SCHEMBL5457252 0.82 HDAC1 (0.48) CNR1LMNAPTPN7CNR2F10
SCHEMBL14463901 0.81 CNR2 (0.48) CNR1CNR2HDAC1HDAC6
SCHEMBL5446567 0.81 L3MBTL1 (0.56) CNR1LMNACNR2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070213359-A1 BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF ACADIA PHARMACEUTICALS INC. (US) 2007-09-13 US disclosed
US-20070213359-A1 BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF ACADIA PHARMACEUTICALS INC. (US) 2007-09-13 US disclosed
US-20070213359-A1 BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF ACADIA PHARMACEUTICALS INC. (US) 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213359-A1 BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF GIPR, GHSR, GHRHR CNR1 65/4885LMNA 3791/4885PTPN7 592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.